Lubiprostone for the Treatment of Adult Women with Irritable Bowel Syndrome with Constipation
| Autor: | Ron Schey, Mahmoud Soubra |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Constipation Tegaserod lubiprostone Population Review Gastroenterology Pharmacotherapy Internal medicine medicine lcsh:RC799-869 education chloride channel 2 Irritable bowel syndrome education.field_of_study business.industry Apical membrane medicine.disease Lubiprostone Diarrhea IBS-C lcsh:Diseases of the digestive system. Gastroenterology women medicine.symptom business Biomedical engineering medicine.drug |
| Zdroj: | Clinical Medicine Insights: Gastroenterology, Vol 5 (2012) Clinical Medicine Insights: Gastroenterology, Vol 2012, Iss 5, Pp 23-30 (2012) Clinical Medicine Insights. Gastroenterology |
| ISSN: | 1179-5522 |
| Popis: | Irritable bowel syndrome with constipation (IBS-C) affects approximately 5% of the population in western countries. The majority of those afflicted are women. Symptoms are often detrimental to the individual's quality of life and incur high healthcare costs to society. There is no evidence to support changes in lifestyle, laxatives or over the counter supplements. Tegaserod appeared to have promising results but was promptly removed from the market due to adverse cardiovascular events. In 2008, lubiprostone (Amitiza) was approved by the US Food and Drug Administration (FDA) for the treatment of women with IBS-C. It is thought to selectively activate type 2 chloride channels in the apical membrane of the intestinal epithelial cells leading to chloride secretion. As result, sodium and water are passively secreted generating peristalsis and laxation, without stimulating gastrointestinal smooth muscle. Several trials with predominantly female patients have shown it to be effective in the treatment of IBS-C. Overall lubiprostone was safe, well tolerated and associated with mostly benign side effects. Nausea and diarrhea were the most commonly reported. Though there are no head to head comparisons with other pharmacological agents, it is our opinion that lubiprostone should be tried as a first line pharmacotherapy for women with IBS-C at a dose of 8 μg BID. Thus far, lubiprostone offers a welcome approach to our narrow therapeutic armamentarium. Further understanding of its mechanism of action may provide additional insight into the pathophysiology of IBS-C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|